Copyright © 2019 EnBiotix, Inc.. All Rights Reserved

EnBiotix has in-licensed ColiFin® from PARI Pharma GmbH, a global leader in nebulized therapies, for worldwide rights ex-Europe.  Approved in Europe since 2010 as a front-line therapy for lung infections in CF, ColiFin® has a proven safety and efficacy track record which EnBiotix is leveraging initially towards the U.S. market. 

Advantages of ColiFin®:

  • Acts via different mechanism of action versus other approved inhaled antibiotics
  • Significantly lower rate of resistance
  • No cross-resistance with other classes
  • Further enables altnernating & combination CF antibiotic therapy

Bridging ColiFin® EU Approval to US CF Standard-of-Care: